Regulatory

IO Shuts Down Following Regulatory Roadblocks

BioSpace

The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma.

Regulatory Read full story

pharminent April 1, 2026 (Last updated: April 1, 2026)

BioSpace

The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma.

Regulatory Read full story

Related Stories

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise